Galderma delivered record net sales of $2.448 billion for the first half of 2025, up 12% year-on-year (constant currency). As a result, the company has raised its guidance for the full year.
The firm stated that all three of its business categories – Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology – contributed to the growth.
Derma skin care growth driven by Cetaphil and Alastin
Its Derma Skincare division, primarily composed of the Cetaphil and Alastin brands, grew by 7.7%. Cetaphil saw “exceptional performance in Asia,” with India becoming a top sales contributor.
In the US market, Cetaphil grew across e-commerce channels and select major retailers, despite constrained consumer spending. Alastin continued to grow at double-digit rates.
Innovative NPD such as Cetaphil’s Acne Fast Rescue Pimple Patches and Alastin’s Restorative Skin Complex with Next Generation TriHex Technology were key drivers of growth, according to the company. Galderma also strengthened its scientific and clinical pipeline with new studies in systemic sclerosis and chronic pruritus.
Strategic campaigns and retail partnerships drive sales
On the marketing front, the company launched CetaSphere, which it described as “a new global advocacy network,” and ran a major Cetaphil campaign in China featuring a leading local live streamer, which saw strong sales during the “618” shopping festival. Alastin also gained more visibility with a high-profile collaboration with Halle Berry at the Met Gala and Cannes Film Festival.
Galderma highlighted its strategic focus on strong retailer engagement, including Alastin’s physician-first approach, targeted execution with local Cetaphil retailers, and fast-growing e-commerce channels.
In other areas of the business, its innovation in injectable aesthetics and therapeutic dermatology also contributed to growth, supported by launches of new “blockbuster” products such as Relfydess.
The company is currently benefiting from rising consumer demand for aesthetic procedures, which are fuelling volume sales, alongside continued consumer interest in science-based derma skin care products.
One area that has recently been a focus for Galderma is the growing use of GLP-receptor drugs such as Ozempic, which has undesirable effects on the skin and facial structure – rapidly creating a more aged appearance. The company has been studying this space and innovating with its products to help tackle these side effects.
US expansion with new Miami HQ
Looking ahead, Galderma said it aims to drive innovation and growth in the US, its largest global market. To support this, it has recently established a new headquarters in Miami, Florida, which will serve as a “strategic hub for Dermatological Skincare and Injectable Aesthetics.”
Commenting on the outlook, Galderma CEO Flemming Ørnskov said the business is aiming to “accelerate growth and move from category leadership to becoming a true powerhouse in dermatology.”
